Physicians should monitor patients for the development of muscle pain and/or weakness in patients on statin therapy, and prompt evaluation, including measurement of CK levels and anti-HMGCR antibodies, should be undertaken if symptoms suggestive of a myopathy arise. Early recognition and intervention are essential for a favorable outcome in these cases. The gene discussed is HMGCR; the disease is myopathy.